Anpario PLC Launch of SAYE Scheme

RNS Number : 2031Q

Anpario PLC

16 December 2024

 

Anpario plc

("Anpario" or the "Company")

 

Launch of SAYE Scheme

 

 

Anpario plc, the independent manufacturer of natural sustainable animal feed additives for health, nutrition and biosecurity, announces that it is launching a Save As You Earn ("SAYE") share scheme for all eligible UK-based employees.

 

The SAYE Scheme allows eligible employees to commit to making a deduction from salary on a monthly basis over three years. At the end of the three-year period eligible employees will be invited to subscribe for options over the Company's Ordinary Shares of 23 pence each ("Ordinary Shares"), subject to certain customary conditions being satisfied. Alternatively, SAYE Scheme Participants may opt to withdraw from the SAYE Scheme, recovering paid-in funds, prior to that time.

 

As agreed with HMRC, the exercise price is to be determined based on a discount of 20% on the average closing middle market price of the Company's Ordinary Shares in the three business days ended on the trading day before the invitation to participate will be made, which is expected on the 19th December 2024.

 

The Executive Directors, Richard Edwards, Marc Wilson and Karen Prior have committed to subscribe to the maximum £500 a month contribution and the related number of options, subject to any scale-back arrangements if the SAYE Scheme is over-subscribed. A further announcement will be made following the date of grant to confirm the total number of share options awards granted under the SAYE scheme.

 

 

 

Enquiries

 

Anpario plc
Richard Edwards, Chief Executive Officer	[phone]
Marc Wilson, Group Finance Director	[phone]
Shore Capital
(Nominated Adviser and Broker)	[phone]
Stephane Auton	Corporate Advisory
David Coaten
Tom Knibbs
Henry Willcocks	Corporate Broking

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

MSCQKABQABDKQBD